<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16554526
   </pmid>
   <datecreated>
    <year>
     2006
    </year>
    <month>
     03
    </month>
    <day>
     23
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     04
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1533-4406
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       354
      </volume>
      <issue>
       12
      </issue>
      <pubdate>
       <year>
        2006
       </year>
       <month>
        Mar
       </month>
       <day>
        23
       </day>
      </pubdate>
     </journalissue>
     <title>
      The New England journal of medicine
     </title>
     <isoabbreviation>
      N. Engl. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Medication augmentation after the failure of SSRIs for depression.
    </articletitle>
    <pagination>
     <medlinepgn>
      1243-52
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation. The primary outcome of remission of symptoms was defined as a score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of this study; scores were obtained over the telephone by raters blinded to treatment assignment. The 16-item Quick Inventory of Depressive Symptomatology--Self-Report (QIDS-SR-16) was used to determine the secondary outcomes of remission (defined as a score of less than 6 at the end of this study) and response (a reduction in baseline scores of 50 percent or more).
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent). Sustained-release bupropion, however, was associated with a greater reduction (from baseline to the end of this study) in QIDS-SR-16 scores than was buspirone (25.3 percent vs. 17.1 percent, P&lt;0.04), a lower QIDS-SR-16 score at the end of this study (8.0 vs. 9.1, P&lt;0.02), and a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P&lt;0.009).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings. Augmentation with sustained-release bupropion does have certain advantages, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events. (ClinicalTrials.gov number, NCT00021528.).
     </abstracttext>
     <copyrightinformation>
      Copyright 2006 Massachusetts Medical Society.
     </copyrightinformation>
    </abstract>
    <affiliation>
     Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9119, USA. madhukar.trivedi@utsouthwestern.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Trivedi
      </lastname>
      <forename>
       Madhukar H
      </forename>
      <initials>
       MH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fava
      </lastname>
      <forename>
       Maurizio
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wisniewski
      </lastname>
      <forename>
       Stephen R
      </forename>
      <initials>
       SR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Thase
      </lastname>
      <forename>
       Michael E
      </forename>
      <initials>
       ME
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Quitkin
      </lastname>
      <forename>
       Frederick
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Warden
      </lastname>
      <forename>
       Diane
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ritz
      </lastname>
      <forename>
       Louise
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nierenberg
      </lastname>
      <forename>
       Andrew A
      </forename>
      <initials>
       AA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lebowitz
      </lastname>
      <forename>
       Barry D
      </forename>
      <initials>
       BD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Biggs
      </lastname>
      <forename>
       Melanie M
      </forename>
      <initials>
       MM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Luther
      </lastname>
      <forename>
       James F
      </forename>
      <initials>
       JF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Shores-Wilson
      </lastname>
      <forename>
       Kathy
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rush
      </lastname>
      <forename>
       A John
      </forename>
      <initials>
       AJ
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       STAR*D Study Team
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <databanklist completeyn="Y">
     <databank>
      <databankname>
       ClinicalTrials.gov
      </databankname>
      <accessionnumberlist>
       <accessionnumber>
        NCT00021528
       </accessionnumber>
      </accessionnumberlist>
     </databank>
    </databanklist>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       N01MH90003
      </grantid>
      <acronym>
       MH
      </acronym>
      <agency>
       NIMH NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, N.I.H., Extramural
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     N Engl J Med
    </medlineta>
    <nlmuniqueid>
     0255562
    </nlmuniqueid>
    <issnlinking>
     0028-4793
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Delayed-Action Preparations
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Dopamine Uptake Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Receptor Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Uptake Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      34841-39-9
     </registrynumber>
     <nameofsubstance>
      Bupropion
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      36505-84-7
     </registrynumber>
     <nameofsubstance>
      Buspirone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      59729-33-8
     </registrynumber>
     <nameofsubstance>
      Citalopram
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2006 Jun 15;354(24):2611-3; author reply 2611-3
     </refsource>
     <pmid version="1">
      16775879
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2006 Mar 23;354(12):1305-7
     </refsource>
     <pmid version="1">
      16554533
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bupropion
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Buspirone
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Citalopram
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Delayed-Action Preparations
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Depressive Disorder, Major
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dopamine Uptake Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Logistic Models
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Remission Induction
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Receptor Agonists
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Uptake Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Failure
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      24
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      4
     </month>
     <day>
      8
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      24
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     354/12/1243
    </articleid>
    <articleid idtype="doi">
     10.1056/NEJMoa052964
    </articleid>
    <articleid idtype="pubmed">
     16554526
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

